Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs CUDC 907 (Primary)
- Indications B cell lymphoma; CNS cancer; Lymphoma; Neuroblastoma; Solid tumours
- Focus Adverse reactions
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 25 May 2017 Acording to a Curis media release, data from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 11 Oct 2016 Status changed from not yet recruiting to recruiting.